Cross-selling advantage of telehealth incumbents
Yazen
The advantage is not just traffic, it is a lower cost and faster path to trust in a category where patients need both medical approval and ongoing coaching. Numan and Manual already had people coming to them for sensitive, recurring treatments like ED, hair loss, and hormone care, plus the clinical workflow to review forms, prescribe remotely, ship medication, and manage follow ups. That lets them add weight loss as another care path inside an existing telehealth machine, instead of building demand and operations from zero.
-
Numan shows what this can look like at scale. It started in men’s health in 2018, added weight loss in 2023, and by 2025 expected roughly $200 million in revenue with weight loss making up the majority. Its app already bundled clinician review, coaching, diagnostics, and recurring subscription billing, so weight loss slotted into habits patients already understood.
-
Manual followed a similar playbook. It launched in men’s health first, then expanded into weight loss, and now operates across the UK, Brazil, and Germany. Its recruiting and product pages show the same reusable infrastructure, asynchronous consultations, prescribers, coaching, and medication fulfillment, applied across multiple conditions.
-
That matters for Yazen because European expansion is not just about entering a new country, it is about entering against companies that may already own the customer relationship. When a patient already buys hair loss or sexual health treatment from Numan or Manual, adding GLP-1 care can be a one click upsell rather than a fresh acquisition.
The market is moving toward multi condition telehealth platforms where obesity care is one product inside a broader subscription relationship. As GLP-1 supply normalizes and more providers offer similar medication access, the winners in Europe are likely to be the companies that combine trusted brand, repeat purchase categories, and local regulatory know how into one cross sell engine.